Premium
Identification, Diagnosis, and Treatment of Acid‐Related Diseases in the Elderly: Implications for Long‐Term Care
Author(s) -
Garnett William R.,
GarabedianRuffalo Susan M.
Publication year - 1997
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1997.tb03784.x
Subject(s) - lansoprazole , omeprazole , medicine , disease , theophylline , proton pump inhibitor , gastroenterology , pharmacotherapy , adverse effect , peptic , maintenance therapy , gerd , gastric acid , helicobacter pylori , intensive care medicine , reflux , pharmacology , peptic ulcer , stomach , chemotherapy
Acid‐related disorders such as peptic ulcer disease and gastroesophageal reflux disease occur frequently in the elderly and are associated with a high frequency of morbidity and mortality. The proton pump inhibitors lansoprazole and omeprazole produce faster rates of healing and greater symptomatic relief in patients with acid‐related disorders than histamine 2 ‐receptor antagonists, are well tolerated, and are associated with few adverse events. Compared with omeprazole, which interacts with diazepam, warfarin, and phenytoin, lansoprazole produces only a minor increase in theophylline clearance. Proton pump inhibitors in combination with antibiotic therapy can eradicate Helicobacter pylori , the main risk factor in the recurrence of peptic ulcer disease, obviating the need for maintenance therapy. Long‐term acid suppression with proton pump inhibitors may be necessary to prevent the recurrence of gastroesophageal reflux disease. The safety and efficacy profile of these agents makes them ideal for the treatment of acid‐related diseases in elderly patients. (Pharmacotherapy 1997;17(5);938–958)